This website is for UK Healthcare Professionals only

Key steps to establishing or expanding your BOTOX® urology service

Whether establishing a new BOTOX® urology service or enhancing your existing service, the first key step is to agree your vision.

Your vision will describe how the service can improve the quality of care and outcomes for patients with overactive bladder (OAB)* or neurogenic detrusor overactivity (NDO)*. It may also describe what you intend your service to look like in 3–5 years’ time and how your service will help to address any gaps or challenges in the local health environment.

Engagement with key stakeholders involved in the care of patients with OAB or NDO will be essential to shape the vision and planning of your service.


Incorporate intermediate steps towards your goal to break down your vision into tangible achievable steps


The role of the nurse cystoscopist

The GIRFT national report on urology acknowledges the key role of nurses in urological services and the importance of nurse development.5

Advantages of the nurse playing a key role, include:

• Nurse specialists are motivated and keen to take on the new role

• It can allow consultant time to be dedicated to emergency care

• Nurse-led outpatient clinics can result in improved waiting times for patients, improved quality of life and better patient satisfaction  


For further information and examples of good clinical practice in line with GIRFT guidance, please request support via the Contact Us page.

Other considerations in order to achieve your vision for your BOTOX® urology service:

  • Operational considerations such as:

o   The procedure itself

o   Equipment

o   Staff and training

o   Available facilities

o   Patient scheduling

  • Creating a patient-centric service: through the provision of pre- and post-procedure patient education and follow-up
  • Securing funding: Gaining financial support for your service is a critical part of the planning process. It is important to:

o   develop a business case

o   estimate the service income

o   identify and engage with the right stakeholders


GIRFT: Getting It Right First Time; OAB: overactive bladder; NDO: neurogenic detrusor overactivity.

BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord  injury (traumatic or non-traumatic), or multiple sclerosis.6

 

References

  1. Allergan. Data on file. INT/0423/2016
  2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
  3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
  4. Allergan Ltd. Data on file 014
  5. Getting It Right First Time. Neurology. Available at: gettingitrightfirsttime.co.uk. Accessed April 2022
  6. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

 

Date of preparation: April 2022. UK-BUO-220017.